BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 28, 2011
View Archived Issues
Data disclosed from several trials assessing velaglucerase alfa in type 1 Gaucher's disease
Read More
Basilea Pharmaceutica discloses more findings from first-in-human trial of BAL-30072
Read More
CHMP issues opinion on new indication for Avastin
Read More
CHMP recommends approval of Prevanar 13 for new indication
Read More
Amarin submits NDA for AMR-101
Read More
Biotie to acquire Newron
Read More
Two Novartis products approved in Japan
Read More
Taliglucerase alfa assessed in Gaucher's disease under French AUT program
Read More
Phase I/II trial investigates polyepitope DNA vaccine in metastatic melanoma
Read More
Progenics discloses preclinical data on humanized MAbs targeting C. difficile toxins
Read More
GSK presents new ITK/TSK inhibitors
Read More
Novel tachykinin NK3 receptor antagonists disclosed by Lundbeck
Read More
Boehringer Ingelheim prepares novel cannabinoid CB2 receptor agonists
Read More
Concert Pharmaceuticals presents novel deuterated compounds
Read More
New cathepsin S inhibitors synthesized
Read More
Extended-release depot formulation of ropivacaine developed by Encore Therapeutics
Read More
Promising results reported on Circassia's ToleroMune Grass hay fever vaccine
Read More
Novo Nordisk files MAAs and plans NDA for insulin products
Read More
Phase I trial of RNAi therapeutic begins in U.K.
Read More
Patient enrollment begins in phase III Wilate study
Read More
Glycopyrrolate formulations show efficacy in randomized phase II trials in COPD
Read More
Photocure and Ipsen to commercialize Hexvix
Read More
CytRx to increase enrollment in INNO-206 clinical trial
Read More
Collegium Pharmaceutical and FDA meet regarding phase III COL-003 program
Read More
Resverlogix set to begin enrollment in ASSURE study
Read More
Abbott Japan and Eisai set to launch new adalimumab formulation
Read More